Metrion Biosciences
Cambridge, GB · Founded 2015 · 42 employees on LinkedIn · 3 known investors
Find your way into Metrion Biosciences
481 people in our graph share verified history with the Metrion Biosciences team — schools, employers, funds. One of them is your warm intro.
Ian Milbournunlockedknows John Ford · together at University of Leeds (overlapped)
×4knows the team · via University of Leeds
×2knows the team · via The Australian National University
knows the team · via UCSF
knows the team · via Exelixis
×2knows the team · via UWC South East Asia
Metrion Biosciences provides ion channel screening and drug discovery services for pharmaceutical and biotech companies. The company specializes in preclinical contract research operations with over 100 years of combined team expertise in ion channel biology.
Founders & leadership
Metrion Biosciences was founded in 2015 by Marc Rogers, John Ford, and Keith McCullagh.
MR
Marc RogersinFounding DirectorMarc Rogers brings over 20 years of ion channel drug discovery experience in the US and UK, including roles in assay development, screening, grant writing, project management, and company founding across biotech and pharmaceutical settings. His work has focused on developing and optimizing automated patch clamp assays for electrophysiology screening and supporting drug development programs for ion channel modulators.
JF
KM
Keith McCullaghinFounding DirectorKeith McCullagh trained in veterinary and experimental pathology at Bristol, Cambridge, and the Cleveland Clinic, and has held research and leadership roles across pharmaceutical development, including Research Director at G D Searle (now Pfizer), founder of British Biotech (the first public biopharmaceutical company in Europe), and CEO of Santaris Pharma, a Danish RNA medicines company acquired by Roche; he founded Pharmacy2u, an online NHS prescription service, and is currently chairman of Metrion Biosciences.
LP
Lee PattersoninChief Executive Officer
Investors · 3
Companies House · registry record
View on Companies House ↗- Registered name
- METRION BIOSCIENCES LTD
- Company number
- 09669815
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 3 Jul 2015
- Registered office
- First Floor, Building 2 Granta Centre, Granta Park, Great Abington, Cambridge, CB21 6AL
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 2 Jul 2026 · next due 16 Jul 2027
Current officers · 8
- Clare Rutty — secretary, appointed 1 Jun 2019
- Steven Alexander Anderson Carle — director, appointed 18 Dec 2023
- John William Ford — director, appointed 1 Dec 2015
- Keith Graham Mccullagh — director, appointed 1 Dec 2015
- David Alan Milroy — director, appointed 4 Dec 2023
- John Gary Montana — director, appointed 1 Feb 2021
- Lee Robert Patterson — director, appointed 6 Dec 2024
- Clare Louise Rutty — director, appointed 4 Dec 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Metrion Biosciences do?
- Metrion Biosciences provides ion channel screening and drug discovery services for pharmaceutical and biotech companies. The company specializes in preclinical contract research operations with over 100 years of combined team expertise in ion channel biology.
- Who founded Metrion Biosciences?
- Metrion Biosciences was founded by Marc Rogers, John Ford, Keith McCullagh in 2015.
- Who are Metrion Biosciences's investors?
- Metrion Biosciences's investors include Gresham House Ventures, Maven Capital Partners, O2h Ventures.
- Where is Metrion Biosciences headquartered?
- Metrion Biosciences is headquartered in Cambridge, GB.